Melatonin entrainment of suprachiasmatic nucleus-regulating circadian rhythms is mediated by MT1 and MT2 receptors. Melatonin also has neuroprotective and mitochondrial activating effects, suggesting it may affect neurodevelopment. We studied melatonin's pharmacological effects on autism spectrum disorder (ASD) neuropathology. Deciduous tooth-derived stem cells from children with ASD were used to model neurodevelopmental defects and differentiated into dopaminergic neurons (ASD-DNs) with or without melatonin. Without melatonin, ASD-DNs had reduced neurite outgrowth, mitochondrial dysfunction, lower mitochondrial Ca levels, and Ca accumulation in the endoplasmic reticulum (ER) compared to control DNs from typically developing children-derived stem cells. Melatonin enhanced IP3-dependent Ca release from ER to mitochondria, improving mitochondrial function and neurite outgrowth in ASD-DNs. Luzindole, an MT1/MT2 antagonist, blocked these effects. Thus, melatonin supplementation may improve dopaminergic system development in ASD by modulating mitochondrial Ca homeostasis via MT1/MT2 receptors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2023.09.050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of melatonin on drug- or contrast-induced acute kidney injury: a systematic review and GRADE-assessed meta-analysis of experimental and clinical studies.
Int Urol Nephrol
January 2025
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran.
Objective: The objective of this systematic review and meta-analysis was to assess the efficacy of melatonin in drug- or contrast-induced AKI in preclinical and clinical studies.
Methods: PubMed, Embase, Scopus, Web of Science (WOS), the Cochrane Database of Systematic Reviews (CDSR), and clinical trials.GOV from the beginning until August 1, 2024.
Biomarkers.
Alzheimers Dement
December 2024
UK Dementia Research Institute, Care Research and Technology Centre, Imperial College London and the University of Surrey, Guildford, UK.
Background: Disruption in diurnal rest-activity rhythms is a hallmark of Alzheimer's disease. Currently, we know little about how physiology, symptoms, and biomarkers change over the 24-hour day in people living with Alzheimer's disease. In particular, we don't know whether plasma biomarkers of neurodegeneration, which offer promise as diagnostic or stratification tools, vary with time of day, and whether these associate with the circadian markers melatonin and cortisol.
View Article and Find Full Text PDFBackground: We present Phase 1 trial data using the Neuropsychiatric Inventory ("NPI") domains, NPI-delusions and NPI-hallucinations as symptoms of psychosis in participants with Alzheimer's ("AD") receiving IGC-AD1, a combination of low concentration delta 9-tetrahydrocannabinol ("THC") and melatonin. Cannabis use is considered an established risk factor for psychosis in young people. Psychosis is prevalent in AD patients, with around 50% experiencing it, generating safety concerns regarding the use of THC in these patients.
View Article and Find Full Text PDFBackground: About half of the patients suffering from Alzheimer's disease (AD) display sleeping disorders. Disruptions in the central circadian clock (CC), located in the brain, accelerate AD pathogenesis, making the CC a promising target. In preclinical trials, this strategy have shown efficacy but clinical results are inconsistent.
View Article and Find Full Text PDFSleep disturbances in Alzheimer's disease (AD) are stressful for patients and families. This review provides an update on the efficacy of melatonin and other interventions for nighttime sleep disturbances in AD patients, building on the original Alzheimer's disease Cooperative Study trial, the first large trial for sleep disturbance in AD. The initial multicenter, randomized, placebo-controlled study investigated the effects of two melatonin formulations - 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!